NO986090L - Phenylalanine derivatives as integrin inhibitors - Google Patents
Phenylalanine derivatives as integrin inhibitorsInfo
- Publication number
- NO986090L NO986090L NO986090A NO986090A NO986090L NO 986090 L NO986090 L NO 986090L NO 986090 A NO986090 A NO 986090A NO 986090 A NO986090 A NO 986090A NO 986090 L NO986090 L NO 986090L
- Authority
- NO
- Norway
- Prior art keywords
- integrin inhibitors
- phenylalanine derivatives
- disseminated
- arteriosclerosis
- thrombosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forbindelser med formel (I) hvor X, Y, Z, R1, R2, R3 og R4 har betydningene angitt i krav l, med det forbehold at minst ett element valgt fra gruppen X, Y, Z må være CH2, samt deres fysiologisk ufarlige salter, kan anvendes som integrininhibitorer, særlig for profylakse og behandling av blodomløpssykdommer, ved trombose, hjerteinfarkt, koronare hjertesyk- dommer, arteriosklerose, osteoporose, ved patologiske prosesser som opp- rettholdes eller spres ved angiogenese, og ved tumorterapi.Compounds of formula (I) wherein X, Y, Z, R1, R2, R3 and R4 have the meanings set forth in claim 1, with the proviso that at least one element selected from the group X, Y, Z must be CH2, as well as their physiologically harmless salts, can be used as integrin inhibitors, in particular for the prophylaxis and treatment of circulatory disorders, in thrombosis, myocardial infarction, coronary heart disease, arteriosclerosis, osteoporosis, in pathological processes maintained or disseminated by angiogenesis, and in tumor therapy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19625929 | 1996-06-28 | ||
DE19654483A DE19654483A1 (en) | 1996-06-28 | 1996-12-27 | Phenylalanine derivatives |
PCT/EP1997/003275 WO1998000395A1 (en) | 1996-06-28 | 1997-06-23 | Phenylalamine derivatives as integrin inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO986090L true NO986090L (en) | 1998-12-23 |
NO986090D0 NO986090D0 (en) | 1998-12-23 |
Family
ID=26027004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO986090A NO986090D0 (en) | 1996-06-28 | 1998-12-23 | Phenylalanine derivatives as integrin inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0907637A1 (en) |
JP (1) | JP2000516575A (en) |
KR (1) | KR20000022190A (en) |
AU (1) | AU3343097A (en) |
CA (1) | CA2259224A1 (en) |
CZ (1) | CZ424998A3 (en) |
NO (1) | NO986090D0 (en) |
PL (1) | PL330915A1 (en) |
SK (1) | SK176898A3 (en) |
WO (1) | WO1998000395A1 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063790A1 (en) * | 1996-05-31 | 2004-04-01 | The Scripps Research Institute | Methods for inhibition of angiogenesis |
DE19705450A1 (en) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclic aromatic amino acids |
US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6313119B1 (en) | 1998-01-23 | 2001-11-06 | Adventis Pharma Deutschland Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
JP2002504534A (en) * | 1998-02-26 | 2002-02-12 | セルテック・セラピューティクス・リミテッド | Phenylalanine derivatives as inhibitors of α4 integrin |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
GB9812088D0 (en) * | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
KR20010086112A (en) * | 1998-12-16 | 2001-09-07 | 빌프리더 하이더 | New Biphenyl and Biphenyl-analogous Compounds as Integrin Antagonists |
US6291503B1 (en) | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
DK1144388T3 (en) | 1999-01-22 | 2010-05-25 | Elan Pharm Inc | Acyl derivatives that treat VLA-4-related disorders |
CN1336921A (en) | 1999-01-22 | 2002-02-20 | 依兰制药公司 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6344484B1 (en) | 1999-02-12 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Tyrosine alkoxyguanidines as integrin inhibitors |
EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
JP2002538135A (en) | 1999-03-01 | 2002-11-12 | エラン ファーマシューティカルズ,インコーポレイテッド | α-aminoacetic acid derivatives useful as α4β7 receptor antagonists |
TR200102944T2 (en) | 1999-04-13 | 2002-08-21 | Basf Aktiengesellschaft | Integrin receptor ligands |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
AU2207001A (en) * | 1999-12-24 | 2001-07-09 | Smithkline Beecham Plc | Novel compounds and process |
JP2003531141A (en) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | Enamine derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
JP2004502762A (en) | 2000-07-07 | 2004-01-29 | セルテック アール アンド ディ リミテッド | Squaric acid derivatives as integrin antagonists containing bicyclic heteroaromatic rings |
EP1305291A1 (en) | 2000-08-02 | 2003-05-02 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
US20020037897A1 (en) * | 2000-08-07 | 2002-03-28 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
KR100854424B1 (en) | 2001-01-29 | 2008-08-27 | 3-디멘져널 파마슈티칼즈 인코오포레이티드 | Substituted indoles and their use as integrin antagonists |
US6872730B2 (en) | 2001-04-27 | 2005-03-29 | 3-Dimensional Pharmaceuticals, Inc. | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
FR2847254B1 (en) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM |
FR2870541B1 (en) | 2004-05-18 | 2006-07-14 | Proskelia Sas | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
ATE502031T1 (en) | 2005-09-29 | 2011-04-15 | Elan Pharm Inc | CARBAMAT COMPOUNDS THAT INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 |
KR20080059268A (en) | 2005-09-29 | 2008-06-26 | 엘란 파마슈티칼스, 인크. | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4 |
CA2643838A1 (en) | 2006-02-27 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
DE102006059317A1 (en) * | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Process for the preparation of β-amino-α-hydroxy-carboxylic acid amides |
CA2760151A1 (en) | 2009-04-27 | 2010-11-04 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08504194A (en) * | 1992-12-01 | 1996-05-07 | メルク エンド カンパニー インコーポレーテッド | Fibrinogen receptor antagonist |
ATE227567T1 (en) * | 1994-05-27 | 2002-11-15 | Merck & Co Inc | PREPARATIONS FOR INHIBITING BONE RESORPTION MEDIATED BY OSTEOCLASTS |
-
1997
- 1997-06-23 JP JP10503812A patent/JP2000516575A/en active Pending
- 1997-06-23 CA CA002259224A patent/CA2259224A1/en not_active Abandoned
- 1997-06-23 EP EP97929258A patent/EP0907637A1/en not_active Withdrawn
- 1997-06-23 WO PCT/EP1997/003275 patent/WO1998000395A1/en not_active Application Discontinuation
- 1997-06-23 KR KR1019980710608A patent/KR20000022190A/en not_active Application Discontinuation
- 1997-06-23 SK SK1768-98A patent/SK176898A3/en unknown
- 1997-06-23 PL PL97330915A patent/PL330915A1/en unknown
- 1997-06-23 AU AU33430/97A patent/AU3343097A/en not_active Abandoned
- 1997-06-23 CZ CZ984249A patent/CZ424998A3/en unknown
-
1998
- 1998-12-23 NO NO986090A patent/NO986090D0/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL330915A1 (en) | 1999-06-07 |
CA2259224A1 (en) | 1998-01-08 |
EP0907637A1 (en) | 1999-04-14 |
WO1998000395A1 (en) | 1998-01-08 |
CZ424998A3 (en) | 1999-03-17 |
NO986090D0 (en) | 1998-12-23 |
AU3343097A (en) | 1998-01-21 |
JP2000516575A (en) | 2000-12-12 |
SK176898A3 (en) | 1999-05-07 |
KR20000022190A (en) | 2000-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO986090L (en) | Phenylalanine derivatives as integrin inhibitors | |
TW372232B (en) | Phenylalanine derivatives | |
NO20010203L (en) | Diacylhydrazine derivatives as integrin inhibitors | |
DK0539086T3 (en) | Condensed pyrimidine derivatives and their use as angiotensin II antagonists | |
NO922147L (en) | HETEROCYCLIC DERIVATIVES | |
NZ514477A (en) | Adamantane derivatives | |
NO984084L (en) | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof | |
NO992821L (en) | Ketobenzamides as Calpain Inhibitors | |
DE69908648D1 (en) | CONDENSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PRODUCTION AND USE | |
RU92004368A (en) | SUBSTITUTED PYRIMIDINES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION | |
NO972881L (en) | Piperazine derivatives, drugs containing them, their use and methods for their preparation | |
NO934501L (en) | Carboxylic acid derivatives, drugs containing these compounds, and process for their preparation | |
CA2280727A1 (en) | Bicyclic amino acids | |
TR200201059T2 (en) | Novel oxabispidine compounds useful in the treatment of cardiac arrhythmias | |
ATE106404T1 (en) | ANGIOTENSIN II ANTAGONISTS. | |
DK0503563T3 (en) | Novel 8-substituted purines as selective adenosine receptor antagonists | |
WO2000021910A3 (en) | 1,2-disubstituted cyclopropanes | |
DK1077218T3 (en) | Peptidomimetic compounds comprising RGD sequences useful as integrin inhibitors | |
CA2348391A1 (en) | Chromenone and chromanone derivatives as integrin inhibitors | |
MY133785A (en) | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | |
ATE109467T1 (en) | USE OF 4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYIDE DERIVATIVES AS FREE RADICAL SCRAPER. | |
NO20020131L (en) | Diacylhydrazinderivater | |
YU22802A (en) | Isonipectoamides for the treatment of integrinmediates disorders | |
NO20020592L (en) | Fluorine derivatives as integrin inhibitors | |
CA2185394A1 (en) | Biotinderivate |